Bryan is an expert software architect and engineer with 20 years of experience in digital product development. Prior to co-founding Limmi, Bryan led product development teams building world-class machine learning and data management , all while revolutionizing how the insurance industry uses and applies artificial intelligence. With a long stint at Viasat as an engineering director, he built embedded systems for simulating massive radio frequency environments and large scale data and AI products for commercial & government applications.
In the past decade alone, Rob served as Thermo Fisher’s Director of Business Development and Americas Marketing, as well as Senior Vice President of Commercial Operations at Sequenom, a groundbreaker in genomic testing in the now rapidly growing noninvasive prenatal testing market. In 2016, Sequenom was successfully transacted to LabCorp. Rob was also President of Specific Diagnostics, a private Silicon Valley based company focused on microbiology (sold to biomerieux). Most recently, Rob was Chief Business Officer of Cardea Bio, that recently sold to Paragraf.
Trevor has spent the past 15 years leading product teams in multiple technology sectors. Prior to Limmi, Trevor served as the CTO of Sea Machines where he built AI powered autonomous marine vessels. He was previously the head of product development at Viasat overseeing data & AI teams for enterprise customers.
Todd has served as CTO of multiple industry leading companies, most recently as VP & CTO of Viasat's fixed broadband business, overseeing investments and technology operations across a $1B business. Todd's deep expertise in AI and data science is invaluable to the team.
Karim Kader, MD, Ph.D., is a board-certified urologist who specializes in detecting, treating, and preventing prostate cancer. Dr. Kader is nationally recognized for his expertise in performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer. He holds several patents for genetic discoveries that show significant promise for early detection and prevention of prostate cancer. He is the principal investigator in numerous clinical research projects and has been published extensively.
